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Multiple myeloma (MM)' remains an incurable malignancy due to marked resistance of tumor cells to standard chemotherapy (1) . Myeloablative therapies requiring hematopoietic stem cell support can effect complete remissions in up to 50% of patients, but relapses are still observed (2) . Consequently, stratagies designed to sustain remissions once marked cytoreduction has been achieved need to be developed. Interferon-a has been employed to some extent in this regard, however, its use and effectiveness is controversial (3) .
Many immunological perturbations have been described in patients with myeloma (4) . Levels of uninvolved immunoglobulin are low, possibly as a result of suppressor macrophages that inhibit immunoglobulin production by normal B cells (5) (6) (7) (8) (9) . In addition, increased numbers of activated T cells and CD8+ cells have been seen in the peripheral blood and bone marrow (10) (11) (12) (13) (14) . NK cell activity is increased in blood and bone marrow, but myeloma cells are resistant to autologous NK cell-mediated lysis (15) (16) (17) (18) (19) . Furthermore, alterations in the number of Fc receptor-bearing cells have been reported, but their function and contribution to the pathophysiology of MM remains to be ascertained (20) .
FcR have been described for all Ig isotypes and the genes for most of these receptors have been cloned and extensively characterized (21) (22) (23) (24) (25) . FcR are present on many cell types and mediate a variety of isotype-specific immunological functions such as antibody-dependent cell cytotoxicity (ADCC), opsonization and phagocytosis (26) (27) (28) (29) (30) (31) . Soluble forms of FcR (sFcR) mediate isotype specific regulation of B cell growth and immunoglobulin production (32) (33) (34) (35) (36) . In a murine model of myeloma, sFcR suppress growth and immunoglobulin production of tumor cells (37) (38) (39) .
In this report, we demonstrate, in untreated patients with IgG-MM, an expansion of CD 16 + cells in the peripheral blood. These CD16 + cells are predominantly CD8 + and shed soluble CD16 (sCD16) that functions as a binding factor for IgG. S-CD16 produced by patient T cells suppresses c-myc transcription and cell growth, as well as immunoglobulin gene transcription and the secretion of Ig in myeloma tumor lines with an IgG isotype. Prolonged treatment of cultured myeloma cell lines with sCD16 results in cell death. Thus, sCD16 is a candidate molecule for adjunctive immunotherapy of human IgG multiple myeloma. 7.4 . A portion of the material was radio-iodinated by the chloramine T method (38) . Radiolabeled material was subjected to analysis by standard sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (38) . Soluble CD16 was isolated, in this fashion, from 6 separate patients with newly diagnosed IgG myeloma. The CD16+ human natural killer cell clone NK3.3 was used as a source of normal sCD16 which was isolated and characterized as described above (42) . Isolation of soluble, human IgA-Fc receptor has been described previously (43) .
Methods
Functional studies. (Fig. 4) . This suppression of tumor cell proliferation and Ig secretion is isotype-specific as sCD16 failed to induce such effects in tumor cell lines producing IgM or IgA (Fig. 5) . Soluble CD16 isolated from five other patients showed similar results (data not shown). Soluble CD16 suppresses transcription ofthe IgH, IgL, and c-myc genes. Northern blot analysis revealed a dose-dependent suppression of the accumulation of mRNA specific for IgH, IgL, and c-myc when ARH-77 cells were treated with JSsCD16, while levels of /3-actin mRNA were unaffected (Fig.   6 ). Anti-human IgG antibody (at 10 Mg/ml) had no effect on IgH, c-myc or,B-actin expression. Anti-IgG antibody, appeared to cause a minor suppression of IgL gene transcription, however, this effect is < 2-fold compared to the > 10-fold suppression mediated by soluble CD16 at the same concentration. Thus, the effect of anti-IgG antibody on IgL transcription is likely not significant. sCD16 had no effect on the half-life of IgH, IgL, or c-myc mRNA in comparison to anti-IgG-treated cells (Fig.   7) (50) . This transmembrane form of CD16 can be released as a soluble form through the action of a cell membrane associated metalloproteinase (51) .
In humans, CD16 is not usually expressed on T cells. An exception to this is seen in Large Granular Lymphocytosis (52) . In this disorder an expansion of CD16+ cells expressing the phenotype of NK cells (CD56 +) or CD8 + T cells is seen (52) . Many of these patients exhibit disorders of granulopoiesis or erythropoiesis suggesting that CD 16 + cells play specific regulatory roles (52) . Abnormalities in immunoglobulin production have also been described in these patients (52) . Thus, this rare disorder suggests the presence of a population of CD8 + CD16 + and CD56+ CD16+ cells that subserve specific roles in the regulation of hematopoiesis and immune cell function. Our results suggest that CD16+ cells are also expanded and play an immunoregulatory role in patients with IgG-secreting multiple myeloma.
Surface immunoglobulin and the action of soluble CD16.
Our data suggests that sCD16 must interact with surface Ig on tumor cell targets in order to effect suppression. (34, 38, 39, 53) . Indeed, surface membrane immunoglobulin is linked to the membrane by additional terminal amino acids, thus leaving the CH2 and CH3 determinants accessible to extracellular effector molecules (54) . All target myeloma cell lines used in our studies express surface Ig. The literature suggests, however, that the plasmacytic myeloma tumor cells in patients are either surface Ig negative or express surface Ig at low density (55) . The presence of surface Ig is an important prerequisite for soluble Fc receptors to exert biological function and hence for their therapeutic use. Recent data in human myeloma indicate the presence of circulating tumor cells with a more immature phenotype including surface Ig expression (56) . Although not firmly established, it has been suggested that these immature tumor cells represent the proliferating, self-renewal compartment in MM. Thus, if future research should establish these sIg+ circulating tumor cells as the proliferative compartment in MM they would be the more appropriate target of sFcR rather than the sIg -plasmacytic tumor cells in the bone marrow.
Suppression of myeloma cell growth by soluble CD16. It is attractive to postulate that the control of tumor cell growth by CD16 is mediated through its suppression of c-myc transcription. The role of inappropriate activation of the c-myc gene has been well established in the murine myeloma model (57) . The role of c-myc in the pathogenesis of human myeloma, however, is less clear. Cytogenetic studies show that chromosome 8 abnormalities, involving the c-myc locus, are present in < 5% of patients with multiple myeloma (58, 59) . Abnormalities of cmyc gene structure, demonstrated by various molecular techniques, are also seen in a small minority of patients (60). cells in newly diagnosed myeloma and in vitro tumor growth suppression upon exposure to sCD16. Does sCD16 control myeloma tumor cell growth in vivo? Benign plasma cell dyscrasias are highly prevalent in the population and increase in incidence with age (64) . Since a minority of these patients progress to overt multiple myeloma it is distinctly possible that expansion of tumor cell clones is prevented in these individuals by immunoregulatory cells. However, since we have not investigated the role of soluble CD16 in these disorders this supposition is entirely speculative. With regard to overt myeloma, however, independent evidence suggests a role for soluble CD16. It is generally believed that myeloma begins years prior to clinical diagnosis. It is possible that accumulated genetic damage in tumor cells coupled with the progressive immune paralysis that accompanies this disease has allowed escape of the tumor clone from immunoregulatory mechanisms. Recent studies reported by Mathiot et al. (65) have suggested a role for sCD16 in the biology of myeloma in vivo. They measured sCD16 in the serum of patients with multiple myeloma and found that the levels correlated inversely with disease stage. These findings do not permit, however, a distinction as to whether lower levels of sCD16 account for or result from tumor mass expansion. 
